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Abstract
Pompe disease is a rare metabolic disorder with available enzymatic replacement therapy. Contrasting with the classic infantile form, the others
subtypes have a heterogeneous presentation that makes an early and accurate diagnosis difficult. We conducted a prospective, multicenter,
observational study to identify undiagnosed patients. During a one-year period, patients followed in Portuguese neuromuscular outpatient clinics
with proximal muscle weakness affecting upper and/or lower limbs, hyperCKemia in two or more determinations or hypotonia and hyperCKemia,
were screened for acid α-glucosidase deficiency by dried blood spots. Lysosomal acid-alpha-1,4-glucosidase activity was determined by tandem
mass spectrometry and positive results were confirmed by molecular study. From the 99 patients screened, Pompe disease was confirmed in 4, with
age of onset ranging from 2.5 to 48 years, all with limb girdle muscle weakness, corresponding to a frequency of 4% in our cohort and 4.9% of
limb girdle muscle weakness. Screening for Pompe disease in high risk populations, using dried blood spots, was already performed in some
European populations. Apart from two negative Scandinavian studies, positive cases were confirmed in 2.8–7.9% of patients presenting with limb
girdle muscle weakness and in 0–2.5% with isolated hyperCKemia.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Pompe disease (PD), glycogen storage disease type II, is a
rare autosomal recessive metabolic disorder caused by deficiency
of the lysosomal enzyme acid-alpha-1,4-glucosidase (GAA). The
dysfunction of this enzyme leads to glycogen accumulation mainly
in skeletal, cardiac and smooth muscles [1,2]. PD1 is classically
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divided in infantile PD1 and late onset PD (LOPD). The classic
infantile form is characterized by hypotonia, progressive weakness,
hypertrophic cardiomyopathy, hepatomegaly, macroglossia and
respiratory failure [2]. There are also cases of infants presenting
with muscle weakness and respiratory failure but without significant
cardiomyopathy, corresponding to the non-classic infantile PD1
subtype. The more common LOPD2 has a heterogeneous
presentation and may present from childhood to late adulthood
with slowly progressive axial and/or limb-girdle muscle weakness,
with or without respiratory symptoms; isolated respiratory failure
or isolated hyperCKemia [2].
The heterogeneity of LOPD2 makes its diagnosis difficult
and usually with a large delay from signs/symptoms onset [3].
The availability of a specific treatment since 2006 warrants a
correct and early diagnosis of this condition [2].
Screening of high risk populations using dry blood spot
(DBS) has been shown to be a reliable method to identify
patients who will benefit for this diagnostic investigation and
reveal phenotypes previously unrelated to PD1 [4].
We conducted a prospective, multicenter, observational study
to identify undiagnosed PD1 in patients followed in Portuguese
neuromuscular outpatient clinics using DBS3as screening method.
2. Patients and methods
Screening for PD1 was part of a national, multicenter,
prospective, observational study (ENDOMUS) promoted by
Portuguese Society for study of Neuromuscular Disorders
(SPEDNM), intended to study selected neuromuscular disorders
in the Portuguese population. During the preparatory phase,
the study was publicized in several national neuromuscular
meetings to encourage the inclusion of as much centers as
possible.
The patients were recruited from neuromuscular outpatient
clinics during one-year-period, between February 2010 and
January 2011. The inclusion criteria were: proximal muscle
weakness affecting upper and/or lower limbs (limb girdle
muscle weakness, LGMW), hyperCKemia in ≥2 determinations
or hypotonia and hyperCKemia. Patients were included if
previous diagnostic workout (clinical evaluation, biochemistry,
genetics, muscle biopsy and EMG) failed to give a definitive
diagnosis.
For each patient, the demographic data, clinical history,
neurological examination and laboratorial studies (biochemistry,
muscle biopsy, EMG, previous molecular studies) were registered
in an electronic case report form.
A DBS3 was obtained in each patient to measure the
lysosomal GAA4 activity by tandem mass spectrometry, using
4-methylumbelliferyl-α-D-glucoside as substrate and acarbose
as inhibitor of maltase-glucoamylase. Blood samples were
collected according to the reference laboratory instructions
(Centro de Genética Médica Jacinto Magalhães). Equivocal
GAA4 activity, due to insufficient blood sample or borderline
GAA enzyme results, was repeated in a second DBS assay by
request of the laboratory. For patients with abnormal
enzymatic activity, a blood sample was collected and sent to
the reference laboratory to confirm the diagnosis of PD1 by
molecular study.
The protocol fulfilled the recommendations of the GCP and
ethical principles deriving from the Declaration of Helsinki.
The study was approved by the Ethics Committee of each center
involved. The electronic case report form meets the legal
requirements of the Portuguese Law for data protection.
Informed consent was obtained from all patients, or from
parents when appropriate.
3. Results
During the study period, 99 patients were included from 13
Portuguese centers. There was a slight female predominance
(58%), with a mean age of 36.1 years (range 3–80 y); 28
patients were under 18 years (28.3%). Twenty-four patients had
positive family history for neuromuscular disorders.
The mean age at symptom onset was 24.9 years, ranging
from congenital to 78 years. Half of the patients had disease
onset in childhood or adolescence and 16% in the first year of
life. The mean disease duration before the inclusion was 15.3
years (range 3–64 y).
Most patients presented with a phenotype of LGMW5
with or without hyperCKemia and only 18% as isolated
hyperCKemia. Symptoms or signs of respiratory involvement
were present in 21.4% and paraspinal muscle weakness was
reported in 27.7%. Seventy-two percent of the patients had
CK levels at least 2 times the upper limit of normal. EMG
was performed in 73 patients and showed a myopatic pattern
in 71.3%. In the 75 patients with muscle biopsy, about half of
them had dystrophic changes and in 7 the report was
suggestive of glycogenosis.
Definitive molecular diagnosis of PD1 was made in 4
patients (Table 1) from different centers. One patient had
positive family history for neuromuscular disorder. All patients
presented with LGMW5, corresponding to 4% of our cohort and
4.9% of patients presenting with LGMW. PD1 patients were
Caucasian, 75% male, with age of onset of symptoms ranging
from 2.5 to 48 years (mean 22.6 y). The mean time to diagnosis
was 19.8 (range 10–42 y).
Respiratory involvement and paraspinal muscle weakness
were present only in the two older patients with disease onset
in adulthood. CK was mildly elevated in all patients (2.7–5
times the upper limit of the normal) and EMG showed myopathic
pattern in the two cases performed. Muscle biopsy was performed
in all patients but only in one was suggestive of glycogenosis.
In other patient muscle biopsy had dystrophic changes with
immunohistochemistry showing weak and irregular dystrophin
staining. Dystrophinopathy was excluded by molecular study
before inclusion in the study. Two ragged red fibers and some
2 Late onset Pompe disease.
3 Dried blood spot.
4 Acid-alpha-1,4-glucosidase. 5 Limb girdle muscle weakness.
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fibers with autophagic vacuoles were also described in this
biopsy. One patient had also left ventricular hypertrophy and
other had facial weakness, dysphagia and atrial fibrillation at
the date of the study. The common c.-32-13T>G GAA gene
mutation was present in all patients, but two new mutations
were also found (one of them in two patients).
4. Discussion
PD1 is a rare metabolic disorder that apart from the less
frequent classic infantile form that has a typical clinical
presentation, has a variable age of onset, form of presentation,
severity and rate of disease progression [1]. The clinical
manifestations of LOPED2 overlap with other neuromuscular
disorders, mainly muscle dystrophies, but also include atypical
clinical features as isolated respiratory failure or non-muscular
symptoms such as scoliosis, hearing impairment and arrhythmia
[5]. Some red flags for the diagnosis of PD1 have been proposed
as the disproportionate axial and respiratory muscle involvement,
in comparison with limb muscle weakness, the presence of
mild non-dystrophic myopathic features on muscle biopsy and
mild CK elevation (usually below 1000) [6]. Muscle biopsy
may reveal excess of glycogen with positive periodic acid-Schiff
material in muscle fibers or vacuoles, EMG may show very
often myotonic discharges, particularly in paraspinal muscles,
but these features are not universally present.
The introduction of enzyme replacement therapy with
alglucosidase alpha has increased the general awareness of this
disease [3], but diagnosis delay is significant and estimated to
be around 7 years from signs/symptoms onset in LOPD2 [7].
Although an accurate and early diagnosis of LOPD2 is difficult
to achieve, early treatment was reported to be associated to a
better efficacy of the therapy [4].
DBS3 has been successfully used to screen for PD1 and is
suggested to be the optimal initial diagnostic test, followed by
biochemical assays on a different tissue and/or genetic analysis
to confirm positive cases [5]. Two DBS3 techniques are
currently available, fluorometry and tandem mass spectrometry,
both with consistent results [5].
Estimated worldwide incidence of all forms of PD1 is 1 in
40,000 live births [1,5], but several studies showed that
incidence rate may vary among different ethnic populations,
ranging from 1:14,000 in an African American population to
1:600,000 in a Portuguese population [7]. There are some data
that permit estimate the prevalence of PD1 in Caucasian to
1–2:100,000 [7]. It is known that PD1 is very rare in
Scandinavia [8].
We used DBS3 to screen patients followed in Portuguese
neuromuscular clinics with undetermined LGMW5 or
hyperCKemia and found 4 new cases of PD (4%). All patients
presented with LGMW5, corresponding to a frequency of
4.9% in this phenotype. We did not found any case of PD1 in
patients with hyperCKemia but this presentation corresponded
only to 18% of our cohort. The delay in the diagnosis was
almost 20 years. The age of onset was variable and the clinical
features suggestive of PD1, as axial muscle weakness and
respiratory symptoms, and muscle biopsy with a glycogen
excess was not present in all our patients as previously
reported in literature.
Screening for PD1 in high risk populations using DBS3 was
already performed in some European populations (Table 2)
both in neuromuscular and respiratory units [4–11]. Apart from
one study that included only patients with asymptomatic or
minimally symptomatic hyperCKemia (mild non-specific
myalgia or mild fatigue) [4], the other cohorts included also
cases of proximal weakness without a definitive diagnosis. In
three studies, patients with myopathy and unspecific muscle
biopsy [6,8,9], and in one, patients with myopathic pattern in
EMG [9], were also included irrespective of clinical
presentation. The number of patients included varied from 82 in
the western Sweden study to 3076 patients in the German and
Britain cohorts, in a total of 4905 patients.
Table 1
Demographic and clinical features of the new cases of Pompe disease.
Age at
symptoms
onset
Gender Limb
weakness
Paraspinal
weakness
Muscle
atrophy
Myalgia Respiratory
symptoms
Other
symptoms
CK GAA activity
(pmol/punch/h)
EMG Muscle
biopsy
GAA mutations
2.5 Male Scapular
girdle
No Yes No No – 4.1 0.56 – Glycogenosis c.-32-13T>G
c.445A>C; p.T149P*
4 Female Pelvic
girdle
No No No No – 2.7 0.11 Myopathic Inconclusive c.-32-13T>G
c.1153delC;
p.R385fsX39*
36 Male Scapular and
pelvic girdle
Yes Yes No Respiratory
failure
Dysphagia,
facial palsy,
atrial
fibrillation
3.6 0.35 – Dystrophic c.-32-13T>G (homo)
48 Male Scapular and
pelvic girdle
Yes Yes Yes Orthopnea Left
ventricular
hypertrophy
5 0.12 Myopathic Inconclusive c.-32-13T>G
c.1153delC;
p.R385fsX391*
CK levels are present as times upper limit of normal.
GAA activity: acid-alpha-1,4-glucosidase activity. Reference values: 4.51–32.7 (pmol/punch/h).
* New mutation according to Erasmus MC GAA gene mutations database.
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Apart from two negative Scandinavian studies, positive
cases were confirmed in all other cohort studies with regard to
patients presenting with LGMW5 or isolated hyperCKemia. In
patients with a limb girdle muscle dystrophy phenotype, PD1
was found with a frequency ranging from 2.8 to 7.9% and in
isolated or paucisymptomatic hyperCKemia from 0 to 2.5%.
These differences in prevalence may be real and due to a
different frequency of PD1 in different countries. However, we
cannot exclude that some of the variation observed in the
different studies is due to methodological bias.
DBS is increasingly recommended in the diagnostic work-up
of patients with unclassified myopathies with proximal weakness
as a useful tool to reach early diagnosis of PD1 [7,10]. DBS3
assay for PD1 could also be considered in patients with
asymptomatic or paucisymptomatic hyperCKemia as a simple
instrument to exclude a treatable neuromuscular disorder.
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